Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Doxil in Androgen Independent Prostate Cancer
NCT00307294Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Mar 2006
- Primary completion
- Jan 2012
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, pegylated liposomal doxorubicin in prostate cancer (PCa), sponsored by University of Pittsburgh. Started Mar 2006; status: completed.
02
Drugs
thalidomidepegylated liposomal doxorubicin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00307294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307294.